A searchable index of real negative results, null findings, and replication failures from the published literature — so you can learn what didn't work before repeating it.
WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record (title, authors, DOI) compiled from open scholarly databases, with the abstract shown in full only where the paper is openly licensed (e.g. Creative Commons); otherwise a short excerpt is shown for reference under fair use. WASTE classifies each work by failure type; classifications are automated and approximate.
21363 results · page 634 of 713
Koch MW, Sage K, Kaur S et al. · 2021 · Neurology
Objective To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon 2-stage design.…
Wilky BA, Julian KA, Maleddu A et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Doxorubicin is standard chemotherapy for metastatic soft tissue sarcomas (STS) but also enhances innate/adaptive immune responses by inducing immunogenic cell death. Most STS are immune "cold" tumors that do not respond to immune…
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Preprint
Abstract Purpose: We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations.…
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Breast cancer research and treatment
Purpose We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations. Methods In…
Comi G, Dadon Y, Sasson N et al. · 2022 · Multiple sclerosis (Houndmills, Basingstoke, England)
Background Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). Objective Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS).…
Manzo A, Sforza V, Carillio G et al. · 2022 · Frontiers in oncology
Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works…
Schiphorst AT, Arquizan C, Turc G et al. · 2026 · Journal of stroke
Background and purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large…
Levy A, Morel D, Texier M et al. · 2025 · Signal transduction and targeted therapy
Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable…
Lenz HJ, Parikh A, Spigel DR et al. · 2024 · Journal for immunotherapy of cancer
Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in…
Pravisano F, Costa J, Marchi L et al. · 2026 · Cancers
The role of adjuvant therapy in stage III melanoma is well established in clinical practice. Because stage IIB-IIC melanoma carries a risk of recurrence and melanoma-specific mortality comparable to that of stage III disease, adjuvant…
Agnihotri G, Lio PA · 2020 · Clinical drug investigation
Multiple pathways contribute to the pathogenesis of atopic dermatitis (AD), and various targeted topical, biologic, and oral systemic agents have subsequently been developed. This review examines the mechanism of action and study designs…
Geurts VCM, Voorwerk L, Balduzzi S et al. · 2023 · Breast (Edinburgh, Scotland)
The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes…
Da Cruz RS, Teague HL, Ramos-Benitez MJ et al. · 2026 · Critical care explorations
Objectives Understanding the mechanistic impact of fostamatinib, a spleen tyrosine kinase inhibitor, in severe COVID-19 using biomarkers associated with disease severity is crucial for the development of host-directed therapeutics. We…
Ishikawa M, Shibata T, Iwata T et al. · 2021 · Gynecologic oncology
Objective To assess the efficacy and safety of dose-dense weekly paclitaxel plus carboplatin (ddTC) with or without bevacizumab compared to conventional, tri-weekly paclitaxel plus carboplatin (cTC) with or without bevacizumab, in…
Juárez-García M, Plasencia-Rodríguez C, Benavent D et al. · 2026 · Therapeutic advances in musculoskeletal disease
Background Axial spondyloarthritis (axSpA) is an inflammatory disease in which, despite expanding therapeutic options, a substantial proportion of patients do not achieve the desired treatment target, highlighting the emerging concept of…
Rimel BJ, Enserro D, Bender DP et al. · 2024 · Cancer
Purpose This paper reports the efficacy of the poly (ADP-ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.…
Marder G, Quach T, Chadha P et al. · 2024 · Rheumatology (Oxford, England)
Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV…
White RA, Mezzano-Robinson V, Shi Q et al. · 2025 · The oncologist
Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine…
Zhang CD, Zhou JS, He LY et al. · 2025 · Frontiers in cardiovascular medicine
Objective The aim of this study was to investigate the quantitative flow ratio (QFR) outcomes in the left circumflex artery (LCX) following the placement of a crossover stent from the left main coronary artery (LM) to the left anterior…
Raychaudhuri R, Cheng HH, Gulati R et al. · 2026 · European urology oncology
Background and objective Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…
Choi SW, Jung HA, Cho HJ et al. · 2023 · Cancer medicine
Background We evaluated the therapeutic efficacy of GC1118, a novel anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification. Methods This study was a multicenter,…
Voglová B, Hladíková Z, Nemétová L et al. · 2020 · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Early worsening of diabetic retinopathy due to sudden glucose normalization is a feared complication of pancreas transplantation; however, its rate or severity has not been studied prospectively. We followed up 43 pancreas and kidney…
Breen WG, Dixon JG, Anderson SK et al. · 2025 · Neuro-oncology
Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose…
Jacobsen LM, Schatz D · 2025 · Hormone research in paediatrics
Background Type 1 diabetes (T1D) is more than an insulin-deficiency disease - it is an autoimmune disease, and the field is moving toward adopting disease-modifying immunotherapy as part of clinical care during T1D development. Summary…
Çalışkan B · 2025 · International ophthalmology
Purpose To evaluate serum lipid profiles with triglyceride-Glucose (TyG) and TG/HDL-c indices in patients with exudative type age-related macular degeneration. Methods A total of 71 participants were included in the study: 35 with…
Davidson TM, Lebreton CL, Hendricksen AEW et al. · 2023 · Gynecologic oncology
Background IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a fully human monoclonal antibody against IGF1R that blocks binding of…
O'Hara MH, Jegede O, Dickson MA et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C of…
Taccetti G, Terlizzi V, Campana S et al. · 2024 · European journal of pediatrics
Bacterial infections of the lower airways are the main cause of mortality and morbidity in cystic fibrosis. The most frequently isolated pathogens are S. aureus and P. aeruginosa; bacterial co-infections are frequently observed. The aim of…
Schott CA, Mohning MP, Cooley JC · 2025 · Seminars in respiratory and critical care medicine
Idiopathic pulmonary fibrosis (IPF) is a rare but devastating diagnosis for patients with only two approved drug therapies. Extensive preclinical studies have identified and characterized novel pathways driving IPF pathogenesis, and…
Mosca M, Arnaud L, Askanase A et al. · 2025 · Lupus science & medicine
Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib 3 mg two times per day dose. Changes in…